STRIDE 1: Effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials
2004
Abstract:Sitaxsentan (SITAX; Thelin®, Encysive Corporation, Bellaire, TX, U.S.A.) is a highly selective oral endothelin-A receptor antagonist. STRIDE-1, a 12-week randomized, doubleblind, placebo-controlled trial of sitaxsentan for pulmonary arterial hypertension showed significant benefit in 6-minu
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
46
Citations
NaN
KQI